Latest Distribution Channels News

RooLife Group has secured a $64 million two-year supply agreement to distribute its branded coffee and food products in China, reinforcing its expansion strategy in the fast-growing market.

BCAL Diagnostics has partnered with US-based ClearNote Health to exclusively distribute innovative blood tests for early detection of pancreatic and ovarian cancers in Australia and New Zealand, starting early 2026.

Merino & Co. has secured a strategic offtake and distribution agreement with Chinese apparel giant BINJORA, marking a significant step into the Chinese market with an initial order exceeding $50,000. The partnership also includes co-branded product development for Australia, leveraging BINJORA’s manufacturing strengths.

Biome Australia Limited projects its Q1 FY26 sales revenue to exceed $5.5 million, breaking its previous quarterly record and signaling continued momentum in the microbiome health sector.

Sports Entertainment Group Limited has finalized its $3.25 million acquisition of RSN's brand and broadcasting assets, signaling a strategic move in Australia's media landscape.

Wellnex Life reported a strong 40.4% revenue increase to $23.6 million in FY25, alongside a 57% improvement in normalised EBITDA loss, signaling progress despite ongoing investment costs.

Osteopore Limited reported a 6% increase in revenue to $1.56 million for the half-year ended June 2025, alongside a slight rise in net loss driven by expanded product development and compliance costs. The company secured key regulatory approvals and broadened its distribution footprint in Asia and the US.

Aumake Limited reported a strong 54% jump in revenue to nearly $40 million for FY25, while cutting its net loss by 45%. The company’s strategic pivot to higher-margin products and key distribution deals set the stage for an ambitious FY26.

Waterco Limited reported a 4% increase in FY25 sales revenue to $249.4 million, driven by regional growth and integration benefits from the Davey acquisition. Despite revenue gains, earnings declined due to cost pressures and restructuring, with statutory NPAT down 31%.

Gale Pacific’s FY25 results reveal resilience amid US market challenges, with growth in Australia and the Middle East offsetting tariff impacts and prompting a major US operating restructure.

NobleOak Life Limited reported a robust 20% growth in in-force premiums and a 22% rise in underlying profit for FY25, surpassing guidance and setting a clear path to $1 billion in-force premium. Strategic partnerships, acquisitions, and product innovation underpin its strong outlook for FY26.

Anagenics has delivered a significant financial turnaround in FY25, driven by a strategic restructure, exiting loss-making operations, and securing new royalty agreements. Despite a revenue dip, the company improved profitability and cash flow, positioning itself for sustainable growth.